- PureTech Health said affiliate Karuna Therapeutics had completed a $68m financing round.

The series B financing included the issuance of $5m in shares upon conversion of debt into equity.

Proceeds would be used to advance the development of KarXT into several new indications, including geriatric psychosis and pain, and to progress new formulations of KarXT.

KarXT, Karuna's lead product candidate, was currently being evaluated in a Phase 2 clinical trial as a potential treatment for acute psychosis in patients with schizophrenia.

At 9:28am: [LON:PRTC] PureTech Health Plc share price was -1.5p at 165.5p

Story provided by